UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_____________________
FORM
8-K
_____________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): May 27, 2010
_____________________
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
_____________________
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
ITEM
7.01
|
REGULATION
FD DISCLOSURE
|
On May
26, 2010, Oramed Pharmaceuticals Inc. issued a press release announcing that the
paper entitled, “Open-label study to assess the safety and pharmacodynamics of
five oral insulin formulations in healthy subjects," authored in March 2010 by
Dr. Roy Eldor, Dr. Miriam Kidron (Oramed's Chief Medical and Technology Officer)
and Dr. Ehud Arbit, was accepted and published in the Diabetes, Obesity and
Metabolism (DOM) journal.
A copy of
the press release is attached to this Current Report on Form 8-K as Exhibit 99.1
and is incorporated by reference herein.
|
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
|
(d)
|
Exhibits
|
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release dated May 26, 2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ORAMED PHARMACEUTICALS
INC.
|
|||
|
Dated:
May 27, 2010
|
|||
|
By:
|
/s/
Nadav Kidron
|
||
|
Nadav
Kidron
|
|||
|
President,
CEO and Director
|
|||
Exhibit
Index
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release dated May 26, 2010.
|
Oramed
Pharmaceuticals Announces Publication of Research Article on its Oral Insulin
Capsule ORMD-0801 in Diabetes, Obesity and Metabolism
Study
data shows ORMD-0801 resulted in glucose and c-peptide reduction
JERUSALEM,
Israel – May 26, 2010– Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB)
(http://www.oramed.com), a developer of alternative drug delivery systems,
announced today that the paper entitled, “Open-label study to assess the safety
and pharmacodynamics of five oral insulin formulations in healthy subjects,"
authored by Dr. Roy Eldor, Dr. Miriam Kidron and Dr. Ehud Arbit, was accepted
and published in the Diabetes, Obesity and Metabolism (DOM)
journal.
"Publication
of our data in a prestigious journal such as DOM lends further credence to the
importance of oral insulin as a potential drug in the management of diabetes.
The data published on formulation optimization is an important milestone in the
development of ORMD-0801, and provides the continued evidence of clinical safety
and the foundation for the proof of concept study for our proprietary oral drug
delivery platform," said Dr. Miriam Kidron, Chief Officer of
Oramed.
About
Oramed Pharmaceuticals
Oramed
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking to
revolutionize the treatment of diabetes through its patented flagship product,
an orally ingestible insulin capsule currently in Phase 2 clinical trials.
Established in 2006, Oramed's technology is based on over 25 years of research
performed by top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in
Jerusalem.
For more
information, please visit http://www.oramed.com.
Safe
Harbor Statement
Some of
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company’s ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company’s filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements.
Company
and Investor Relation Contacts:
Oramed
Pharmaceuticals Inc.
Tara
Horn
Office:
646-240-4193
Cell: +
972-54-334-4318Email: tara@oramed.com